These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 37582701)
1. Tumor to liver maximum standardized uptake value ratio of FDG-PET/CT parameters predicts tumor treatment response and survival of stage III non-small cell lung cancer. Zhang P; Chen W; Zhao K; Qiu X; Li T; Zhu X; Sun P; Wang C; Song Y BMC Med Imaging; 2023 Aug; 23(1):107. PubMed ID: 37582701 [TBL] [Abstract][Full Text] [Related]
2. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer. Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer. Tong AN; Han SR; Yan P; Gong H; Zhao H; Yao H; Wang YM Med Oncol; 2014 Jan; 31(1):780. PubMed ID: 24326983 [TBL] [Abstract][Full Text] [Related]
4. Prognostic importance of Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790 [TBL] [Abstract][Full Text] [Related]
5. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy. Yan H; Wang R; Zhao F; Zhu K; Jiang S; Zhao W; Feng R Acta Radiol; 2011 Jul; 52(6):646-50. PubMed ID: 21508201 [TBL] [Abstract][Full Text] [Related]
6. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer. Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391 [TBL] [Abstract][Full Text] [Related]
7. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy. Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134 [TBL] [Abstract][Full Text] [Related]
8. Prognostic role of baseline Dondi F; Albano D; Bellini P; Cerudelli E; Treglia G; Bertagna F Clin Imaging; 2023 Feb; 94():71-78. PubMed ID: 36495848 [TBL] [Abstract][Full Text] [Related]
9. Metabolic tumor volume derived from Ding C; Mao X; Li N; Huang M; Huang Z; Bao W; Li H; Fan J Hell J Nucl Med; 2022; 25(1):63-70. PubMed ID: 35503557 [TBL] [Abstract][Full Text] [Related]
10. Tumor angiogenesis at baseline identified by Wei Y; Qin X; Liu X; Zheng J; Luan X; Zhou Y; Yu J; Yuan S J Transl Med; 2022 Feb; 20(1):63. PubMed ID: 35109866 [TBL] [Abstract][Full Text] [Related]
11. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection. Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069 [TBL] [Abstract][Full Text] [Related]
12. Primary tumor standardized uptake value (SUVmax) measured on Hui Z; Wei F; Ren H; Xu W; Ren X J Cancer Res Clin Oncol; 2020 Oct; 146(10):2595-2605. PubMed ID: 32494919 [TBL] [Abstract][Full Text] [Related]
13. The value on SUV-derived parameters assessed on Liao X; Liu M; Li S; Huang W; Guo C; Liu J; Xiong Y; Zhang J; Fan Y; Wang R BMC Med Imaging; 2023 Apr; 23(1):49. PubMed ID: 37020286 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer. Nakanishi K; Nakamura S; Sugiyama T; Kadomatsu Y; Ueno H; Goto M; Ozeki N; Fukui T; Iwano S; Chen-Yoshikawa TF BMC Cancer; 2021 Sep; 21(1):983. PubMed ID: 34474680 [TBL] [Abstract][Full Text] [Related]
15. Is post-treatment standardized uptake value a prognostic factor in unresectable non-small cell lung carcinoma? Yılmaz U; Yasar Z; Korkmaz E; Yalcın B; Koparal H; Ozbilek E Med Glas (Zenica); 2017 Aug; 14(2):204-210. PubMed ID: 28698535 [TBL] [Abstract][Full Text] [Related]
16. Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer. Dong X; Sun X; Sun L; Maxim PG; Xing L; Huang Y; Li W; Wan H; Zhao X; Xing L; Yu J PLoS One; 2016; 11(6):e0157836. PubMed ID: 27322376 [TBL] [Abstract][Full Text] [Related]
17. Luan X; Huang Y; Gao S; Sun X; Wang S; Ma L; Teng X; Lu H; Yu J; Yuan S Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2336-2342. PubMed ID: 27631310 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369 [TBL] [Abstract][Full Text] [Related]
19. Role of Yuan H; Tan X; Sun X; He L; Li D; Jiang L Jpn J Radiol; 2023 May; 41(5):521-530. PubMed ID: 36480105 [TBL] [Abstract][Full Text] [Related]
20. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. Machtay M; Duan F; Siegel BA; Snyder BS; Gorelick JJ; Reddin JS; Munden R; Johnson DW; Wilf LH; DeNittis A; Sherwin N; Cho KH; Kim SK; Videtic G; Neumann DR; Komaki R; Macapinlac H; Bradley JD; Alavi A J Clin Oncol; 2013 Oct; 31(30):3823-30. PubMed ID: 24043740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]